Skip to content
Baltimore News Journal – Lifestyle
Author:
Sunshine Biopharma Inc.
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
October 9, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
October 8, 2026
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
September 24, 2026
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
September 16, 2026
Health Canada Approves Sunshine Biopharma’s Atenolol for Treating and Managing Cardiovascular Conditions
August 31, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
August 19, 2026
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
August 7, 2026
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
August 4, 2026
Health Canada Approves Sunshine Biopharma’s Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
July 28, 2026
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
July 20, 2026
1
2
Next Page
→